{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:12:59Z","timestamp":1777493579752,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Despite frequent use of antipsychotic medications to target severe behavioral problems among children with intellectual disabilities (ID), there is little information as to the extent to which adverse effect monitoring is in place for this population. The aim of this pilot study was to determine the extent to which monitoring for adverse effects was documented in health records of a cohort of children with ID who had been prescribed antipsychotic medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were available on all children referred to a mental health clinic at a children's hospital in Canada who had ID and behavioral difficulties with intake appointments between September 1, 2016 and November 30, 2017. Charts of all those on antipsychotic medications were reviewed for a 12-week period to determine the extent to which adverse effect monitoring was documented using the parameters stipulated by the Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA), including laboratory, anthropometric, and neurological measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The database was composed of 47 patients of whom 25 were on antipsychotics (56% boys; mean age 13 [SD 3] years). The most commonly used antipsychotic was risperidone (48%). The extent of adherence to the guidelines was (1) 96% for weight, height, and body mass index; (2) 84% for extrapyramidal symptom screening; (3) 80% for blood pressure; (4) 64% for abdominal girth and liver enzymes; (5) 60% for fasting plasma glucose; and (6) 56% for fasting lipids. Only 20% had all core recommended parameters documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>There were significant gaps in adverse effect monitoring in this cohort. Examination of variation in larger samples from multiple clinical services are required to determine the extent of this quality care gap. Several barriers to adherence are proposed with suggested solutions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2018.0167","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T10:38:40Z","timestamp":1551263920000},"page":"235-240","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Adherence to Antipsychotic Adverse Effect Monitoring Among a Referred Sample of Children with Intellectual Disabilities"],"prefix":"10.1177","volume":"29","author":[{"given":"Khodadad R.","family":"Javaheri","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"McLennan","sequence":"additional","affiliation":[{"name":"Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada."},{"name":"Department of Pediatrics, University of Calgary, Calgary, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"e_1_3_2_2_1","first-page":"492","article-title":"Psychometric Characteristics of the Aberrant Behavior Checklist.\u201d","volume":"89","author":"Aman M","year":"1985","unstructured":"Aman M, , Singh NN, , Stewart AW, , Field CJ: Psychometric Characteristics of the Aberrant Behavior Checklist.\u201d. Am J Ment Defic, 89:492\u2013502, 1985a.","journal-title":"Am J Ment Defic"},{"key":"e_1_3_2_3_1","first-page":"485","article-title":"The Aberrant Behavior Checklist: A Behavior Rating Scale for the Assessment of Treatment Effects","volume":"89","author":"Aman M","year":"1985","unstructured":"Aman M, , Singh NN, , Stewart AW, , Field CJ: The Aberrant Behavior Checklist: A Behavior Rating Scale for the Assessment of Treatment Effects. Am J Ment Defic, 89:485\u2013491, 1985b.","journal-title":"Am J Ment Defic"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.596"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rasd.2012.08.001"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717751693"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/inm.12417"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2014.224"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078390317752444"},{"key":"e_1_3_2_10_1","first-page":"976","article-title":"Practice Parameters for the use of Atypical Antipsychotic Medication in Children and Adolescents","volume":"52","author":"Findling RL","year":"2013","unstructured":"Findling RL, , Drury SS, , Jensen PS, , Rapoport JL, , Bukstein OG, , Walter HJ, , Benson S, , Chrisman S, , Farchione TR, , Hamilton J, , Keable H, , Kinlan J, , Schoettle U, , Siegel M, , Stock S: Practice Parameters for the use of Atypical Antipsychotic Medication in Children and Adolescents. Am Acad Child Adolesc Psychiatry, 52:976\u2013990, 2013.","journal-title":"Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.5690"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2011.10.009"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595559"},{"key":"e_1_3_2_14_1","first-page":"575","article-title":"Management Recommendations for Metabolic Complications Associated with Second-Generation Antipsychotic Use in Children and Youth","volume":"16","author":"Ho J","year":"2011","unstructured":"Ho J, , Panagiotopoulos C, , McCrindle B, , Grisaru S, , Pringsheim T: Management Recommendations for Metabolic Complications Associated with Second-Generation Antipsychotic Use in Children and Youth. Paediatr Child Health, 16:575\u2013580, 2011.","journal-title":"Paediatr Child Health"},{"key":"e_1_3_2_15_1","first-page":"292","article-title":"Evaluation of monitoring for metabolic effects in children treated with second generation antipsychotics in a pediatric clinic","volume":"18","author":"Honey BL","year":"2013","unstructured":"Honey BL, , Ramos L, , Brahm NC: Evaluation of monitoring for metabolic effects in children treated with second generation antipsychotics in a pediatric clinic. J Pediatr Pharmacol Ther, 18:292\u2013297, 2013.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3263-x"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/79.3.379"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.01.001"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.575"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-016-2946-7"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013171"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2010.48"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2012.647"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2016.03.012"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205701202"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743718779950"},{"key":"e_1_3_2_27_1","first-page":"1094","article-title":"Monitoring Antipsychotic Safety in Children with Tourette Syndrome and ADHD: A Prospective Study","volume":"29","author":"Pringsheim T","year":"2014","unstructured":"Pringsheim T, , Hammer T, , McLennan JD, , Sarna J: Monitoring Antipsychotic Safety in Children with Tourette Syndrome and ADHD: A Prospective Study. Movement Disord, 29:1094, 2014.","journal-title":"Movement Disord"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2018.09.099"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0145"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/16.9.590"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/16.9.581"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-0828"},{"key":"e_1_3_2_33_1","first-page":"134","article-title":"Barriers and Facilitators to Implementation of a Metabolic Monitoring Protocol in Hospital and Community Settings for Second-Generation Antipsychotic-Treated Youth","volume":"20","author":"Ronsley R","year":"2011","unstructured":"Ronsley R, , Raghuram K, , Davidson J, , Panagiotopoulos C: Barriers and Facilitators to Implementation of a Metabolic Monitoring Protocol in Hospital and Community Settings for Second-Generation Antipsychotic-Treated Youth. J Can Acad Child Adolesc Psychiatry, 20:134\u2013141, 2011.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205700504"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-016-2712-x"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/1362361313497537"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2013.0099"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0049"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2000.10.79"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2018.0167","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2018.0167","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2018.0167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:23Z","timestamp":1777388123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2018.0167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1089\/cap.2018.0167"],"URL":"https:\/\/doi.org\/10.1089\/cap.2018.0167","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}